GlaxoSmithKline's chronic obstructive pulmonary disease drug Nucala receives approval for marketing in the European Union.

On February 6th, GlaxoSmithKline announced that the European Commission has approved its monoclonal antibody maintenance therapy drug Nucala for uncontrolled chronic obstructive pulmonary disease. GlaxoSmithKline stated that this approval is based on positive data from the MATINEE phase III clinical trial. There are over 390 million global patients with COPD, including approximately 40 million in Europe.